📈 Gross Profit History (8 Quarters)
🧮 NVSEF Gross Profit Breakdown
Understanding Gross Profit
Gross Profit is Revenue minus Cost of Revenue (also called Cost of Goods Sold or COGS). It measures how much a company earns from selling its products before subtracting operating expenses. For NVSEF, the trailing twelve month gross profit is $40.8B.
Why Gross Profit Matters
Gross margin (Gross Profit / Revenue) is one of the most important indicators of pricing power and competitive advantage. Companies with high and stable gross margins typically have differentiated products, strong brands, or unique capabilities.
NVSEF's gross profit growth rate of 3.04% (based on log-linear regression of 8 quarters) indicates modest positive growth in gross profit.
Gross Margin: The Key Metric
NVSEF's gross margin of N/A shows what percentage of each sales dollar remains after paying direct production costs.
Gross Profit vs Other Profitability Metrics
Operating Income: $17.6B →
Gross Profit minus operating expenses (SG&A, R&D). Shows profitability after all operating costs but before interest and taxes.
Net Income: $14.0B →
The bottom line after all expenses including interest and taxes. The final measure of accounting profit.
Free Cash Flow: $17.6B →
Actual cash generated after capital expenditures. Can differ significantly from gross profit due to working capital and capex.
Revenue: $54.5B →
The top line that gross profit is derived from. Gross margin shows what percentage becomes gross profit.
Summary: NVSEF Gross Profit Trend
Novartis AG (NVSEF) generated $40.8B in trailing twelve-month gross profit, growing at 3.04% annually — positive but below the 10% level Zyberno considers strong growth. For complete financial analysis, view the full NVSEF stock report on Zyberno.
Frequently Asked Questions
What is NVSEF's current gross profit?
Novartis AG's trailing twelve month (TTM) gross profit is $40.8B, growing at 3.04% annually — positive but below the 10% level Zyberno considers strong growth.
Is NVSEF's gross profit growing?
Novartis AG (NVSEF) generated $40.8B in trailing twelve-month gross profit, growing at 3.04% annually — positive but below the 10% level Zyberno considers strong growth.
What is NVSEF's gross margin?
Novartis AG (NVSEF) generated $40.8B in trailing twelve-month gross profit, growing at 3.04% annually — positive but below the 10% level Zyberno considers strong growth.
What is the difference between gross profit and net income?
Gross profit is Revenue minus Cost of Revenue only. Net income also subtracts operating expenses, interest, and taxes. NVSEF's gross profit is $40.8B versus net income of $14.0B.
📊 Full NVSEF Stock Report →
See NVSEF's intrinsic value, margin of safety, DCF valuation, and complete financial analysis with 250+ metrics.
💵 NVSEF Free Cash Flow →
Compare to Free Cash Flow which subtracts all capital expenditures, not just maintenance CapEx.
💰 NVSEF Owner Earnings →
Compare to Buffett's Owner Earnings metric which uses maintenance CapEx instead of total capital expenditures.
📈 NVSEF Earnings Per Share →
Analyze EPS trends, P/E ratio, earnings yield, and per-share profitability metrics.
🎯 NVSEF Earnings Surprise (SUE) →
See whether NVSEF is beating or missing its own earnings trend — Standardized Unexpected Earnings and post-earnings drift.
📊 NVSEF Revenue →
Analyze revenue trends, growth rate, P/S ratio, and top-line sales performance.
💰 NVSEF Net Income →
Analyze the bottom-line profit, P/E ratio, and net profit margin trends.
🔶 NVSEF Operating Income →
Analyze EBIT, operating margin, and core business profitability before interest and taxes.
💜 NVSEF Gross Profit →
Analyze gross margin, pricing power, and profitability before operating expenses.